Register Login

Abiopharma

  • Home
  • About
  • Newsroom
  • Company List
  • Events
  • Automated Tools
  • Contact

News list

Centessa Pharmaceuticals plc (CNTA)

  • Event
  • July 08, 2022, 20:32 UTC
  • 20
  • 1 comments

(99% Neutral) CENTESSA PHARMACEUTICALS PLC (CNTA) Announces Executive Departure

Comment Full text

Amphastar (AMPH)

  • Event
  • July 08, 2022, 20:25 UTC
  • 19
  • 1 comments

(99% Neutral) Amphastar Pharmaceuticals, Inc. (AMPH) Announces Business Combination

Comment Full text

Nurix Therapeutics Inc (NRIX)

  • Event
  • July 08, 2022, 20:13 UTC
  • 20
  • 1 comments

(99% Neutral) NURIX THERAPEUTICS, INC. (NRIX) Announces Business Combination

Comment Full text

Sanofi (SNY)

  • Event
  • July 08, 2022, 15:01 UTC
  • 19
  • 1 comments

(10% Negative) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

Comment Full text

Kymera Therapeutics Inc (KYMR)

  • Event
  • July 08, 2022, 11:45 UTC
  • 19
  • 1 comments

(99% Neutral) KYMERA THERAPEUTICS, INC. (KYMR) Announces New Board Appointment

Comment Full text

Provention Bio Inc (the company became a subdivision of the company Sanofi ADR (SNY)) (PRVB)

  • Event
  • July 08, 2022, 11:25 UTC
  • 18
  • 1 comments

(99% Neutral) Provention Bio, Inc. (PRVB) Announces Business Combination

Comment Full text

OptiNose Inc (OPTN)

  • Event
  • July 08, 2022, 11:00 UTC
  • 17
  • 1 comments

(75% Positive) OPTINOSE, INC. (OPTN) Provides Update on deep for chronic

Comment Full text

Legend Biotech (LEGN)

  • Event
  • July 07, 2022, 12:31 UTC
  • 17
  • 1 comments

(10% Negative) Legend Biotech (LEGN) Announces Clinical Development Update (Form 6-K)

Comment Full text

Guardant Health Inc (GH)

  • Event
  • July 07, 2022, 12:08 UTC
  • 20
  • 1 comments

(99% Neutral) GUARDANT HEALTH, INC. (GH) Files Form 8-K

Comment Full text

Intercept Pharmaceuticals Inc (was acquisited by Alfasigma (Italy) on 08/11/2023) (ICPT)

  • Event
  • July 07, 2022, 11:30 UTC
  • 20
  • 1 comments

(10% Negative) Intercept Pharmaceuticals, Inc. (ICPT) Announces Delay in announced Trials for OCA in liver fibrosis due to NASH Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Comment Full text
  • Previous
  • 562
  • 563
  • 564
  • 565
  • 566
  • Next

Search

News categories

  • Technical Exchange News(12514)
  • Event(6229)
  • SEC News(283979)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(162129)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin